ARZERRA Plus Chlorambucil Achieved a Significantly Greater Response Rate vs Chlorambucil Alone (P<0.001)1

Response Rates for ARZERRA Plus Chlorambucil vs Chlorambucil Alone

  • 37% of patients who achieved CR with ARZERRA plus chlorambucil also achieved minimal residual disease (MRD) negativity
  • No patients on chlorambucil alone with CR achieved MRD negativity

Learn more about the study design and patient characteristics.

References: 1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2016. 2. Hillmen P, Robak T, Janssens A, et al, for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873-1883.